2
8 2010 . N 341- " 9 " "
1
9 17 1998 N 157- " " , :
" 9.
1. , , , , , , , , , .
2. , , , .".
2 1 2011 .
.
, 8 2010 N 341-
3
BD SoloShotTM IX - , .
1., . , .
2. , , .
3. , .
4. . - .
5. . .
6. .
. . , . 0,5 1 .
7. .
8. , , , . 0,5 1
9. .
10. . , .
11. ,
1., , . . . . , 2009 .
2. . . 10 2007 ., 31 (416).
3.Koster MP, Stellato N, Kohn N. Rubin LG. Needle length for immunization of early adolescents as determined by ultrasound..Pediatrics. 2009; 124 (2)::667-672
|
|
|
4.Ipp M., Taddio A., Sam J. et al Vaccine-related pain: randomized controlled trial of two injection techniques. Arch Dis Child 2007;92:1105-1108
5.Plotkin S, Orenstein W, Offit P. Vaccines. 5th ed. Saunders, 2008.
6.Aronson N.E., Santosham M., Comstock G.W. et al. Long-term efficacy of BCG vaccine in American Indians and Alaska Natives: A 60-year follow-up. JAMA 2004;291 (17):2127-2128
7.WHO. Weekly epidemiol. Rec. 2007; 82 (3): 17-24
8.D.S. Kernodle. Decrease in the effectiveness of bacille Calmerte-Guerin vaccine against pulmonary tuberculosis: a consequence of increased immune suppression by microbial antioxidants, not overat-tenuation. Clinical Infectious Diseases 2010; 51(2):177-184
9.Kaufmann S... Hussey G., Lambert P. New vaccines for tuberculosis. Lancet 2010; 375: 2110-2119
10. .. , , , , . . . . 2006, 23
11.Mackie CO., Buxton J.A.. Tadwalkar S., Patrick D.M. Hepatitis immunization strategies: liming is everything CMAJ 2009; 180 (2):196-202)
12.Hepatitis vaccines. WHO position paper. Weekly epidemiological record. 2009 No. 40, 84, 405-420. World Health Organization Geneva.
13.Abu Sin M., Zenke R., Roenckendorf R et al. Pertussis outbreak in schools inLudwigslust. Germany demonstrating the role of waning immunity. Pediatr. Inf. Dis. J. 2009; 28 (3): 242-245
14.Glanz J.M., McClure D.L., Magid DJ.et al. Parental refusal of pertussis vaccination is associated with an increased risk of penussis infection in children Pediatrics 2009; 123; 1446-1451
15.Pertussis epidemic in California may be worst in 50 years. Infection control today 24.06.2010
16. . - . . . ., 2005. 38 .
17.Vidor ., Plotkin S.A.. Immunogenicity of a two-component (PT & FHA) acellular pertussis vac-cine in various combinations. Human Vaccines 2008; 4:5, 328-340
18.Robbins J. ., Schneerson R., Keith J.M. et al. Pertussis vaccine. A Critique. Pediatr Infect Dis J 2009;28: 237-241
19.Wei S. C. Talli K., Cushing K. Et al.Effectiveness of adolescent and adult tetanus.reduced-dose diphtheria, and acellular penussis vaccine against pertussis. Vaccine 2009; 27: 1504-1510.
20.Wan-Ting Huang, Gargiullo P.M., Broder K. R. et al. Lack of association between acellular pertussis vaccine and seizures in early childhood. Pediatrics 2010; 126 (2): e263-e269
21.Red Book 2009: Report of the Committee on infectious diseases. 27* ed. Elk Grove Village. . American Academy of Pediatrics, 2009.
22.Imported Vaccine-Associated Paralytic Poliomyelitis United Stales, 2005 MMWR - Fcbnnm 3, 2006: 55(04): 97-99
23.Leuridan E., Hens N.. Hutse V., et al.Early waning of maternal measles antibodies in era of measles elimination: longitudinal study BMJ 20I0;340: 1626
24.Hashimoto H. Fujioka M, Kinumaki H, et al. An office-based prospective study of deafness in mumps. Pediatr. Infect. Dis J. 2009; 28 (3):173-175
25.Plotkin S. A. Is Japan Deaf to Mumps Vaccination? Pediatr. Infect. Dis J. 2009; 28 (3): 176
26.Peltola H., Jokinen S., Paunio M. et al. Measles, mumps, and rubella in Finland: 25 years of a na-tionwide elimination programme, www.thelancet.com/infection Vol 8 December 2008: 796-803
|
|
|
27. ... ... .. . .. . . -,- 2002.- 175 .
28.. . 2: . , , 2001. WHO/V&B/00.36
29.Klein N. P.. Fireman ., Yih W. ., et al. Measles-Mumps-Rubclla-Varicella combination vaccine 30.and the risk of febrile seizures Pediatrics 2010; 126 (l):el-e8
30.WHO Writing Committee of the consultation on clinical aspects of pandemic (H1N1) 2009 influenza. Clinical aspects of pandemic 2009 influenza a (HlNl) virus infection. NEJM 2010; 362 (18):1708-1719
31.Baker M.G.. Wilson N.. Huang Q.S. et al. Pandemic influenza A(H1N1) in New Zealand: the experience from April to August 2009. Euro Surveill 2009; 14:pii 19319-pii 19319.
32.Ross ., Zimmer S.. Burke D. et al. Seroprevalence following the second wave of pandemic 2009 HlNl influenza. PLoS Curr Influenza 2010; February 24:RRN1148.
33. WHO. who.int/csr/disease/swineflu/notes/briefing20091222/en/index.html
34. ... , A (H1N1), . 2010; 1: 3-9
35. 2009-2010 . http://www.epidemiolog.ru/situation/index.php? ELEMENT JD=92I8
36. .. . 2009 . .. , 2010
37. Garcia-Garcia. L. Partial protection of seasonal trivalenl inactivated vaccine against novel pandemic influenza A/HI N1 2009: case-control study in Mexico City. BMJ, Online t edition, Oct. 7. 2009.
38. Loeb M et al. Effect of influenza vaccination of children on infection rates in Hutterite communities: A randomized trial. JAMA 2010 Mar 10; 303:943.
39. Siriwardena A. N.. Gwini S.M.. Coupland CSlat . .. Influenza vaccination, pneumococcal vaccination and risk of acute myocardial infarction: matched case-control study. CMAJ 2010. DOl:l0.1503/cmaj.091891
40. . . 3. . . . . 1999. 5:10
41. .., ... .. . 2001; 5-6. . 39-44
42. Jansen A. G.S.C.. Sanders E.A.M.. Hoes A. W.et al. Effects of influenza plus pneumococcal conjugate vaccination versus influenza vaccination alone in preventing respiratory tract infections in children: A randomized, double-blind, placebo-controlled trial. J. Pediatr. 2008; 153:764-770
43. 2007-2008 - 19.06.08 JfsO 1/6424-8-32
44. Poeling KA. Edwards KM. Weinberg GA. et al. The under-recognized burden of influenza in young children. N Engl J Med 2006; 355:31-40
45. Iskandera M Booya R.. Lambert S. The burden of influenza in children. Curr. Opin. Infect. Dis. 2007;20:259-263
46. Halasa N. .. Gerber M. A.. Chen Q. et al. Safety and immunogenicity of trivalent inactivated influenza vaccine in infants JID 2008:197 (15 May):1448-1454
47. Cates C. Jefferson . A. Rowe B. Vaccines for preventing influenza in people with asthma. Cochrane Database Syst Rev. 2004;2:CD000364.
48. De Keyser J. Zwanikken , Boon M Effects of influenza vaccination and influenza illness on exacerbations in multiple sclerosis. J Neurol Sci 1998 Jul I5;159(l):51-53
49. A.E. . 5 . ..2007; 3: 10-17.
50. . MP 3.3.1. 2009 . 2009
|
|
|
51. Ladhani S.. Heath P. .. Slack M. P. E. et al. Haemophilus influenzae serotype b conjugate vacciee failure in twelve countries with established national childhood immunization programmes. Clin Mj-crobiol Infect 2010; 16: 948-954
52. ... .., .. . Hib- , , 3 . .20065 5, (2). - . 6-11
53. . .. . .-. .. (.). 2007. 464 .
54. . Committee on infectious diseases. Recommendations for the prevention of streptococcus pneumoniae infections in infants and children: Use of 13-valent pneumococcal conjugate vaccine (PCV13) and pneumococcal polysaccharide vaccine (PPSV23). Pediatrics 2010; 126 (1):186-190
55. Spencer D. Current European pneumococcal epidemiology and immediate need fofr broader serotype coverage. Sinflorix symposium. 27lb Annual ESP1D meeting/ Brussels, May, 2009.
56. Vesterheum D., Lovoll O.. Aaberge l.S. et al. Effectiveness of a 2+1 dose schedule pneumcoccal conjugate vaccine programme on invasive pneumococcal disease among children in Norway. Vaccine 2008; 26: 3277-3281
57. Ipp M.. Parkin P.C., Lear N. et al. Order of Vaccine Injection and Infant Pain Response Arch Pe-diatr Adolesc Med 2009; 163 (5)" 469-472
58. French N el al. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N. Engl J Med 2010 Mar 4; 362:812.
59. Jansen A.. Sanders E.. Yjts A. et al. Effects of influenza plus pneumococcal conjugate vaccination versus influenza vaccination alone in preventing respiratory tract infections in children: a randomized, double-blind, placebo-controlled trial.. J. Pediatr.2008; 153 (6): 764-770
60. Pavia M., Bianco A., C. Nobile et al. Efficacy of pneumococcal vaccination in children younger than 24 months: a meta-analysis. Pediatrics 2009;123 No. 6 June, pp. el 103-el 110
61. Invasive Pneumococcal Disease in Children 5 Years After Conjugate Vaccine Introduction - Eight States. 1998-2005 MMWR 2008 57(06|;I44-148
62. Pneumococcal conjugate vaccine for childhood immunization - WHO position paper. Weekly epi-demiol. Rec. 2007; 82 (12): 93-104
63. Hsu H. Shutt K.A., Moore M.R et al. Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N. Eng. J. Med. 2009; 360 (3): 244256
64. Tsai C.J.. Griffin M.R., Nuorti J.P. et al. Changing Epidemiology of Pneumococcal Meningitis after the Introduction of Pneumococcal Conjugate Vaccine in the United States Clinical Infectious Diseases 2008;46:1664-1672
65. Centers for Disease Control and Prevention. Pneumonia hospitalizations among young children before and after introduction of pneumococcal conjugate vaccine: United States. 1997-2006. MMWR Morb. Mortal. Wkly. Rep. 2009;58 (1):1 -4
66. Zhou F., Shefer A, Yuan Kong.Nuorti J.P. Trends in acute otitis media-related health care utilization by privately insured young children in the U S. 1997-2004 Pediatrics 2008;121 (2):253-260
67. Vila-Corcoles A.. Ochoa-Gondar O. et al. Protective effects of the 23-valent pneumococcal polysaccharide vaccine in the elderly population: The EVAN-65 Study. CID 2006:43:860-868
68. Vila-Corcoles A., Salsench E., Rodriguez-Bianco T. et al. Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in middle-aged and older adults: A matched case-control study. Vaccine 2009; 27: 1504-1510
69. Maruyama ., Taguchi O, Niederman M.S. et al. Efficacy of 23-valent pneumococcal vaccine in preventing pneumonia and improving survival in nursing home residents: double blind, randomised and placebo controlled trial. BMJ 20l0;340:cl004
|
|
|
70. Lamontagne F.. Garanl M.-P.. Carvalho J.-C. Et al. Pneumococcal vaccination and risk of myocardial infarction CMAJ 2008;179(8):773-777
71. , , Hib- . . , . .2005 .
72. .., .. 2008:16 (9): 604-606.
73.Cameron J.C.. Allan G- Johnston F. Et al. Severe complications of chickenpox in hospitalized children in the UK and Ireland. Arch Dis Child 2007;92:1062-1066
74.Shakhanina 1.. Gorelov .. Lydrjne L, Tolkushin A. Economic assessment of regional vaccina! prevention program against varicella in Moscow. Europedialrics, Moscow, 2009. R498
75. ... ... .. . . . . ( ). . .2008.5 (3): 6-14
76. Marin M. Meissner . . Seward J. F. Varicella prevention in the united states: A review of successes and challenges. Pediatrics 2008; 122 (3): 744-751
77. Krelh H. W Lee B.W.. Kosuwon Pet al. (). Biodrugs 2008: 22 (6): 387-402
78. ... ... .. . . , . 2010. 7.4 .34-36
79. PROTECT. The Pediatric Burden of Rotavirus Disease in Europe. Epidemi. and Infection, 2006; 134 (5):908-916.
80. Meszner. Z; Balogh A., Banyai K. et al. The Clinical Burden of Rotavirus Disease: Retrospective Analysis of Infant and Childhood Gastroenteritis in Seven Countries in Central and Eastern Europe. Pediatr. Inf. Dis. J 2008,27 (1) Suppl.l: S33-S41
81. Gleizes O.. Desselberger U.. Tatochenko V. et al. Nosocomial rotavirus infection in European countries. A review of the epidemiology, severity and economic burden of hospital-acquired rotavirus disease. Pediatr. Inf. Dis. J 2006. 25 (1) Suppl. 12-21
82. Foppa IM. Karmaus W. Ehlken B. et al. Health care-associated rotavirus illness in pediatric inpatients in Germany. Austria, and Switzerland.lnfect Control Hosp Epidemiol 2006; 27: 633-635.
83. European Society for pediatric infectious diseases/European society for pediatric gastroenterology, hepatology. and nutrition. Evidence-based recommendations for rotavirus vaccination in Europe. J. Pediatr.c Gastroenterol & Nulr 2008; 46. Suppl 2: S38-S48,
84. Zaman K.. Shin S., Anh D. Et al The pentavalent rotavirus vaccine protects against rotavirus Gastroenteritis caused by diverse rotavirus serotypes for two years of follow-up in Asia. 26* Congress, Johanessburg. 2010: 556
85. Harper D.M. Prophilactic human papillomavirus vaccines to prevent cervical cancer" review of the Phase II and HI trials. Future Medicine Therapy 2008-.5 93):331-324
86. Olsson J. et al. Quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and external genital disease in subjects with prior HPV type infection. EUROGIN 2008. Nice, 12-15, SS1-3
87. ... .. : - . : 14- . . . . . 2008; . 1: 99-108.
88. Offit P.A.. Quarles J.. Gerber M.A. et al. Addressing parents' concerns: do multiple vaccines overwhelm or weaken the infant's immune system? // Pediatrics. - 2002; 109(1): 124-129
89 Empfehlungen der Standigen Impfkomission (STIKO) am Robert Koch-InstitutlStand Juli 2004. Epidemiologisches Bulletin 24 Juli 2004 Nr30
90. Carbone ., MeEntire ., Kissin D. et al. absence of an increase in cardiorespiratory events after diphiheria-tetanus-acellular pertussis immunization in preterm infants: a randomized, multicenter study. Pediatrics 2008; 121 (5): el085-1090
91. .. , , - . . . . . 2006. 45 .
92. T.A. - . . . . 2006,45 .
93. Nilsson A, De Milito A. et al. Current chemotherapy protocols for childhood acute lymphoblastic leukemia induce loss of humoral immunity to viral vaccination antigens. Pediatrics 2002;109:e91-6
|
|
|
94.. CM, .., .. .. .. - . , 2004, -V2(7), . 26-30
95. Esposito S., Cecinati V., Brescia L.et al. Vaccinations in children with cancer. Vaccine 2010; 28:3278-84
96. Gershon AA. Steinberg SP. Persistence of immunity to varicella in children with leukemia immunized with live attenuated varicella vaccine. N Engl JMed 1989;320:892-897.
97. Esser M.. Cotton M.. De Beer Et al. the HIV exposed infant - not infected but affected. 26* IPA Congress. Johanessburg. 2010: 14
98. .. , - . . . . ..2006.48 .
99. . . 2: . , . 2001, WHO/V&B/00.36
100. S. .. Kohl K.S., Dagan R. et al. Fever as an adverse event following immunization: case definition and guidelines of data collection, analysis, and presentation. Vaccine 2004; 22: 551-556
101. Lin N. D- Kleinman K., Chan K. A., et al. Multiple vaccinations and the risk of medically attended fever. Vaccine 2010: 287 4169-4174
102. Rothstein E.. Kohl K.S.. Ball L. Et al. Nodule at injection site as an adverse event following immunization: casedefinilion and guidelines for data collection, analysis, and presentation/ Vaccine 2004: 22:575-585
103. Bonhoeffer J., Vermeer P., Halperin S. et al. Persistent crying in infants and children as an adverse event following immunization: case definition and guidelines for data collection, analysis, and presentation Vaccine 2004; 22: 586-591.
104. Bonhoeffer J.. Gold M.S.. Heijbel H.et al. Hypotonic-Hyporesponsive Episode (HHE) as an adverse event following immunization: case definition and guidelines for data collection, analysis. and presentation/ Vaccine 2004; 22: 563-568
105. Bonhoeffer J., Menkes J., Gold M. S. et al. Generalized convulsive seizure as an adverse event following.immunization: case definition and guidelines for data collection, analysis, and presentation. Vaccine 22 (2004) 557-562 559
106. Barlow W.E.. Davis R.L.. Glasser J.W. et al. The risk of seizures after receipt of whole-cell pertussis or measles, mumps, and rebella vaccine. N. Engl. J. Med. 2001; 345:65
107. Institute of Medicine. Adverse effects of pertussis and rubella vaccines.. National Academy Press: Washington. DC, 1991, 378 p.
108. Wood R. A.. Berger M Dreskin S.C. et all. An algorithm for treatment of patients with hypersensitivity reactions after vaccines.Pediatrics 2008; 122 (3): e771-778
109. ... . . .. . . 2009.
110. Pollard G.A. Jacobson R.M. Understanding those who do not understand: a brief review of the anti-vaccine movement. Vaccine 2001; 19:2440-2445
111. Siegrist C.-A., Lewis E.M., Eskola, J. et al. Human papilloma virus immunization in adolescent and young adults: a cohort study to illustrate what events might be mistaken for adverse reactions. Pe-diatr. Infect. Dis. J.. 2007:26 (11): 979-984.
112. Callreus ., Svanstrom H.. Nielsen N.M. et al.Human papillomavirus immunisation of adolescent girls and anticipated reporting of immune-mediated adverse events Vaccine 2009; 27: 2954-2958.
113. Goodman M. J., Nordin, J. D.. Belongia E.A. et al. Henoch-Schoenlein purpura and polysaccharide meningococcal vaccine. Pediatrics 2010; 126 (2): e325-e329
114. Hviid A.. Wohlfahrt J.. Stellfeld V Melbyt M. Childhood vaccination and nontargeted infectious
disease hospitalization. JAMA 2005: 294 (6): 699-705
115. Stowej J., Andrews N.. Taylor B-. Miller E. No evidence of an increase of bacterial and viral infections following Measles, Mumps and Rubella vaccine. Vaccine 2009; 27: 1422-1425
116. Shann F. Heterologus immunity and the nonspecific effects of vaccines: a major medical advance? Pediatr. infect. Dis.J.2003: 23(61:555-558
117. Smith MJ., Woods C.R., On-time vaccine receipt in the first year does not adversely affect neuropsychological outcomes Pediatrics 2010; 125:1134-1141
118. Mohrenschlager M, Haberl VM, Kramer U. Behrendt H. Ring J. Early BCG and pertussis vaccination and atopic diseases in 5- to 7-year-old preschool children from Augsburg, Germany: Results from the MIRIAM study. Pediatr Allergy Immunol 2007 18: 5-9
119. Spycher B. D., Silverman M., Egger M. et al. Routine Vaccination Against pertussis and the risk of childhood asthma: A population-based cohort study/ Pediatrics 2009; 123 (3):944-950
120. Hviid A.. Melbye M Measles-mumps-rubella vaccination and asthma-like disease in early childhood. American Journal of Epidemiology. Am J Epidemiol 2008:168 (11): 1277-1283
121. Matheson M.C., Walters H..E, Burgess J.A. et al. Childhood immunization and atopic disease into middle-age - a prospective cohort study. Pediatr Allergy Immunol 2010: 21: 301-306
122. Rottem M. Asthma prevalence in children: is there an association with childhood vaccination'1 Expert rev. Clin. Immunol. 2008; 4(6): 687-694
123. Rosenlund H.. Bergstro". A., Aim J. et al. Allergic disease and atopic sensitization in children in relation to measles vaccination and measles infection. Pediatrics 2009; 123 (3):771-778
124. Ray P.. Hay ward J.. Michelson D. Et al. Encephalopathy After Whole-Cell Pertussis or Measles Vaccination. Lack of Evidence for a Causal Association in a Retrospective Case-Control Study. Pediatr Infect Dis J 2006;25: 768-773
125. Berkovic S.. Harkin L. McMahon J. et al. De-novo mutations of the sodium channel gene SCN1A in alleged vaccine encephalopathy: a retrospective study. Lancet Neurol 2006; 5:488-92
126. Mcintosh A.M.. McMahon J., Dibbens L. M. Et al. Effects of vaccination on onset and outcome of Dravet syndrome: a retrospective study, www.thelancet.com/neurology 2010 June; (9): 592-598
127. Mikaeloff Y.. Caridadc G.. Rossier M. Et al. Hepatitis Vaccination and the risk of childhood-onset multiple sclerosis. Arch. Pediatr. Adolesc. med. 2007; 161 (12):l 176-1182
128. Stowe J.. Andrews N.. Wise L. Miller E. Investigation of the temporal association of Guillain-Barrer syndrome with influenza vaccine and influenzalike illness using the united kingdom general practice research database Am. J, Epidemiol. Advance Access Nov 24, 2008
129. Centers for Disease Control and Prevention (CDC). Preliminary results: Surveillance for Guillain-Barre syndrome after receipt of influenza A (HIN1) 2009 monovalent vaccine United States. 2009-2010. MMWR Morb Mortal Wkly Rep 2010 Jun 4:59:657.
130. Bedford H., Elliman D.A. MMR vaccine and autism. BMJ 2010:340: 655
131. Pichichero M.E.. Gentile A., Giglio. N. et al. Mercury levels in newborns and infants after receipt of thimerosal-containing vaccines. Pediatrics 2008; 121 (2):e208-e214
132. Thompson W. W Price C, Goodson B. Et. Al. Early Thimerosal exposure and neuropsychological outcomes at 7 to 10 years. Nrw Eng. J. Med. 2007; 357 (13):1281-I292
133. Prymula R., Siegrist C.-A.. Chlibek R. Et al. Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials www.thelancet.com Vol 374 October 17. 2009: 1339-1350
134. Pisacane A., Continisio P., Palma O. et al. Breastfeeding and risk for fever after immunization Pediatrics 2010; 125, (6): el448-el454
135. Goraya J.S.. Virdi V.J.S. Treatment of BCG-lvmphadenitis: a metaanalysis. Pediatr. Infect. Dis. J. 2001; 20(6): 632-634.
136. Singla A., Singh S.. Goraya J.S. The natural course of nonsuppurative Calmette-Guterin bacillus lymphadenitis. (Brief Reports] Pediatr. Infect. Dis. J. 2002: 21(5): 446-448
137. Price C.S.. Thompson W.W.. Goodson B. et al. Prenatal and infant exposure to thimerosal from
vaccines and immunoglobulins and risk of autism. Pediatrics 2010;126:656-664
1.1 5
1.2 6
1.3 10
1.4 13
1.5 . .. . 19
1.6 25
1.7 29 1.7 29
1.9 , (32) 31
1.10 , 32
